Clinical trial
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain…
NCT00069940 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00069940 |
|---|---|
| Title | Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor |
| Official title | A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor, Sarcoma |
| Intervention type | Biological |
| Interventions | sargramostim, telomerase: 540-548 peptide vaccine |
| Start date | Dec 1, 2000 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2008 |
| First posted | Oct 7, 2003 |
| Last update posted | Dec 28, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: